VASO 最新10-Q变化
将 VASO 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-14 与上一份 10-Q · 2026-05-15
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +47 | −24 | ~6 | 4 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~4 | 0 |
| 法律诉讼 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
| 其他信息 | 文字有新增/删除 | +5 | −3 | ~2 | 11 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)、风险因素
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-14
●IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc. (“VasoTechnology”), primarily focuses on managed network technology services. As described in Note C, the NetWolves managed network services operations are reported as discontinued operations and no longer included in segm…
●Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively, primarily focuses on the design, manufacture, sale and service of…
The Company has ended its operations in the IT segment after the sale of VHC-IT in November 2025 and the sale of NetWolves in July 2026.
Unless otherwise noted, this Management’s Discussion and Analysis of Financial Condition and Results of Operations relates solely to our continuing operations and does not include the operations of NetWolves. See Note C – Discontinued Operations of the notes to condensed consolidated financial state…
Results of Operations – For the Three Months Ended June 30, 2026 and 2025
相对上期删除的文字 · 来源:10-Q · 2026-05-15
●IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc. (“VasoTechnology”), primarily focuses on managed network technology services. We divested our former healthcare IT service business in November 2025;
●Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp.…
Results of Operations – For the Three Months Ended March 31, 2026 and 2025
Total revenue for the three months ended March 31, 2026 and 2025 was $19,356,000 and $19,462,000, respectively, representing a decrease of $106,000, or less than 1% year-over-year. On a segment basis, revenue in the professional sales service and equipment segments increased $530,000 and $118,000, r…
Revenue in the IT segment for the three months ended March 31, 2026 was $9,561,000 compared to $10,315,000 for the three months ended March 31, 2025, a decrease of $754,000, or 7%, of which $987,000 resulted from the divestiture of the VasoHealthcare IT business in the 4th quarter of 2025, partially…
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-08-14
3(ii) Bylaws (Incorporated by reference to Registration Statement on Form S-18, No. 33-24095).
10.1 Transaction Award Agreement between Vaso Corporation and Peter Castle
10.2 Amendment to Transaction Award Agreement between Vaso Corporation and Peter Castle
31.1 Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
相对上期删除的文字 · 来源:10-Q · 2026-05-15
3(ii) Amended and Re-stated Bylaws (Incorporated by reference to Report on Form 8-K filed February 12, 2026).
31.1 Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议